Overview：Chronic inflammatory arthritis (Rheumatoid Arthritis (RA), peripheral forms of seronegative spondylitis (SpA) etc.) is a group of chronic inflammatory disorder that may affect various joints. The only way to stop the progression of the disease and improve the quality of life of these patients is using of Disease Modyfing Anti Rheumatic Drugs (DMARD).  Biological DMARDs (bDMARDs) can only be used if other conventional   DMARDs have not adequately controlled your inflammatory arthritis such as rheumatoid arthritis.

Features：Biologic DMARDs target specific molecules, cells and pathways that cause inflammation and damage tissue. They are more effective than traditional DMARDs.

Procedure：Some of these bDMARDs are monoclonal, chimeric humanized fusions antibodies, while others are receptors that have been fused to a part of the human immunoglobulin or small molecules such as Janus kinase (JAK) inhibitors.

Notification：The most concerning adverse effect of all biologic DMARDs is an increased risk of common and serious infections, including bacterial, fungal, and viral infections. Reactivation of tuberculosis, herpes zoster, and hepatitis B/C can also occur.

Estimated cost：For estimated medical costs, please contact International Medical Services Center.